Illumina, Inc. $ILMN Shares Sold by Natixis Advisors LLC

Natixis Advisors LLC cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 301,038 shares of the life sciences company’s stock after selling 16,803 shares during the quarter. Natixis Advisors LLC’s holdings in Illumina were worth $39,484,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ILMN. Elyxium Wealth LLC acquired a new stake in Illumina in the 4th quarter valued at $25,000. Board of the Pension Protection Fund purchased a new stake in Illumina in the 4th quarter worth $26,000. Creative Capital Management Investments LLC raised its position in Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new position in Illumina during the fourth quarter valued at $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Illumina during the fourth quarter valued at $26,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ILMN. Weiss Ratings cut shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Canaccord Genuity Group decreased their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Citigroup lifted their price objective on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Guggenheim increased their target price on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a report on Monday. Finally, Barclays raised their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $138.38.

Insider Activity

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the sale, the chief accounting officer directly owned 14,446 shares in the company, valued at $2,311,360. This trade represents a 3.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total value of $97,328.00. Following the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,002,371 shares of company stock valued at $155,472,900 over the last three months. 2.90% of the stock is currently owned by corporate insiders.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Illumina Stock Performance

Shares of Illumina stock opened at $170.93 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market capitalization of $25.86 billion, a price-to-earnings ratio of 31.08, a price-to-earnings-growth ratio of 2.69 and a beta of 1.50. The business has a 50-day moving average of $136.19 and a 200 day moving average of $133.03. Illumina, Inc. has a 12 month low of $81.75 and a 12 month high of $172.49.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the business earned $0.97 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 5.2 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.